Mustang Bio (MBIO)
(Delayed Data from NSDQ)
$0.26 USD
+0.01 (4.88%)
Updated May 1, 2024 03:59 PM ET
After-Market: $0.27 +0.01 (3.81%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBIO 0.26 +0.01(4.88%)
Will MBIO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBIO
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
MBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
Other News for MBIO
MindBio Eyes Senior Exchange Amidst Promising Trials
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
MindBio Launches Pioneering Women’s Health Drug Trials
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues